Published in Przegl Lek on January 01, 2006
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol (2012) 1.56
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood (2012) 1.50
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood (2012) 1.09
IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett (2005) 0.97
Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol (2011) 0.96
Immunoglobulin D myeloma--problems with diagnosing and staging (own experience and literature review). Leuk Lymphoma (2005) 0.92
TGF-beta1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine (2006) 0.91
Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma. Med Oncol (2009) 0.90
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med (2015) 0.90
microRNAs: fine tuning of erythropoiesis. Cell Mol Biol Lett (2012) 0.89
Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol (2004) 0.87
Palmitoylation of MPP1 (membrane-palmitoylated protein 1)/p55 is crucial for lateral membrane organization in erythroid cells. J Biol Chem (2012) 0.86
Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol (2005) 0.85
Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res (2011) 0.85
Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm (2006) 0.85
Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res (2004) 0.85
Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. Postepy Hig Med Dosw (Online) (2013) 0.83
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit (2005) 0.83
[Nasopharyngeal carcinoma coexistent with lymph node tuberculosis, diagnostic difficulties--case report]. Otolaryngol Pol (2005) 0.82
IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia. J Cancer Res Clin Oncol (2014) 0.82
Increased percentage of CD8+CD28- suppressor lymphocytes in peripheral blood and skin infiltrates correlates with advanced disease in patients with cutaneous T-cell lymphomas. Postepy Hig Med Dosw (Online) (2009) 0.81
A novel L1340P mutation in the ANK1 gene is associated with hereditary spherocytosis? Br J Haematol (2014) 0.81
High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients. Med Oncol (2013) 0.81
Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathol Oncol Res (2011) 0.81
VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma. Biomed Res Int (2013) 0.81
[Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma]. Pol Arch Med Wewn (2003) 0.80
Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells. Mol Cell Biochem (2010) 0.79
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis (2009) 0.79
High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease. Eur J Haematol (2009) 0.79
Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas. Oncol Rep (2009) 0.79
Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma. Hematology (2015) 0.78
Asymmetric dimethylarginine in hematological malignancies: a preliminary study. Leuk Lymphoma (2008) 0.78
High incidence of ancestral HLA haplotype 8.1 and monoclonal incomplete DH-JH immunoglobulin heavy chain gene rearrangement in persistent polyclonal B-cell lymphocytosis. Ann Hematol (2008) 0.78
[Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients]. Pol Arch Med Wewn (2004) 0.78
Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation. Ann Noninvasive Electrocardiol (2013) 0.78
A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations. Haematologica (2011) 0.78
Expression of cyclin A and bone morphogenetic protein receptors and response to induction therapy in patients with acute leukemias. Leuk Lymphoma (2011) 0.78
Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes. Folia Histochem Cytobiol (2006) 0.78
[Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas]. Pol Arch Med Wewn (2005) 0.78
Expression of Eph A4, Eph B2 and Eph B4 receptors in AML. Pathol Oncol Res (2014) 0.78
High expression of hematopoietic cell specific Lyn substrate-1 (HS1) predicts poor survival of B-cell chronic lymphocytic leukemia patients. Leuk Res (2012) 0.78
[Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia]. Pol Arch Med Wewn (2002) 0.78
[Familial incidence of myelodysplastic syndromes]. Wiad Lek (2006) 0.77
VEGF and bFGF gene polymorphisms in Polish patients with B-CLL. Med Oncol (2013) 0.77
Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma. Eur J Clin Invest (2014) 0.77
[Expression of p16INK4a, p15INK4b, p21WAF1/Clip1 cell cycle inhibitors on blastic cells in patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) ]. Pol Arch Med Wewn (2002) 0.77
The expression of Toll-like receptors and development of severe sepsis in patients with acute myeloid leukemias after induction chemotherapy. Med Oncol (2014) 0.76
Expression of metallothionein (MT) and gluthatione s-transferase pi (SGTP) in the bone marrow of patients with myeloproliferative disorders (MPD). Folia Morphol (Warsz) (2004) 0.76
IFN gamma gene polymorphism may contribute to the susceptibility to CLL. Pathol Oncol Res (2009) 0.76
Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study). Blood Coagul Fibrinolysis (2017) 0.75
Liposome-coated lipoplex-based carrier for antisense oligonucleotides. Cancer Biol Ther (2015) 0.75
Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials. Eur J Haematol (2013) 0.75
[Whipple's disease as a complication of chronic lymphocytic leukemia treated with fludarabine]. Pol Arch Med Wewn (2002) 0.75
[Anagrelide in the treatment of thrombocythemia essential (ET)]. Pol Arch Med Wewn (2004) 0.75
[Cytogenetic changes and their prognostic significance in elderly acute myeloid leukemia]. Pol Arch Med Wewn (2003) 0.75
The role of soluble HLA-G and HLA-G receptors in patients with hematological malignancies after allogeneic stem cell transplantation. Med Oncol (2015) 0.75
[Leukemoid reaction with uncommonly high leucocytosis in the course of serious infection]. Wiad Lek (2006) 0.75
[CD-133, a new marker for normal hematopoietic progenitor and stem cells, their leukemic counterparts and endothelial precursors]. Pol Arch Med Wewn (2003) 0.75
[Plasma concentration of the shed form of L-selectin (sL-selectin) in patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) and its relation to the clinical course]. Pol Arch Med Wewn (2004) 0.75
[Factor VII deficiency--case report]. Pol Arch Med Wewn (2006) 0.75
[Thalidomide-induced sensory neuropaty in patients with multiple myeloma]. Pol Merkur Lekarski (2011) 0.75
Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Blood Coagul Fibrinolysis (2015) 0.75
Blood serum levels of soluble forms of adhesion molecules ICAM-1 (sICAM-1) and selectin E (s-selectin E) in patients with various phases of non-Hodgkin's lymphomas. Med Sci Monit (2002) 0.75
[Mastocytosis--diagnostic criteria and treatment]. Postepy Hig Med Dosw (Online) (2009) 0.75
[Assessment of hematopoiesis regeneration in patients with solid tumors after radiotherapy]. Pol Arch Med Wewn (2004) 0.75
[Coexistence of pneumoconiosis with myelodysplastic syndrome in a coal miner occupationally exposed to coal dust]. Med Pr (2005) 0.75
[Extramedullary hematopoiesis in inguinal lymph nodes in the course of osteomyelofibrosis--case report]. Pol Arch Med Wewn (2004) 0.75
[Amyloidosis in the course of multiple myeloma]. Pol Arch Med Wewn (2005) 0.75
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.75
Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia. Anal Quant Cytol Histol (2004) 0.75
Increased expression of vascular endothelial growth factor in bone marrow of multiple myeloma patients. Eur J Intern Med (2003) 0.75
ICOS gene polymorphisms in B-cell chronic lymphocytic leukemia in the Polish population. Folia Histochem Cytobiol (2011) 0.75
[Anxiety and depressive symptoms in patients treated due to haematologic malignancies]. Psychiatr Pol (2005) 0.75
The expression of proliferating cell nuclear antigen (PCNA) and of nucleolar organizer regions (AgNORs) correlates with the morphological type of bone marrow plasma cells in multiple myeloma (MM). Pol Arch Med Wewn (2003) 0.75
Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. Pharmacol Rep (2011) 0.75
[The role of endothelial cells and endothelial precursor cells in angiogenesis]. Przegl Lek (2006) 0.75
[Non-typical leukemic metastases localization in bulbus oculi and vertebral column and in thyroid gland and trachea in the course of chronic lymphocytic leukemia--two case reports]. Pol Arch Med Wewn (2005) 0.75
Pregnancy in a woman with polycystic ovary syndrome and myelodysplastic syndrome (in the form of refractory anemia) treated with allogeneic hemopoietic stem-cell transplantation (alloHSCT). Gynecol Endocrinol (2010) 0.75
The use of hyperbaric oxygen therapy in the treatment of hemorrhagic cystitis after allogeneic stem cell transplantation from an unrelated donor. Int J Hematol (2015) 0.75
CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase. Acta Haematol (2014) 0.75